Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial
Kavita Singh,Paushali Mukherjee,Ahmad Rushdi Shakri,Ankita Singh,Gaurav Pandey,Meenakshi Bakshi,Geetanjali Uppal,Rajender Jena,Ankita Rawat,Purnima Kumar,Rukmini Bhardwaj,Syed Shams Yazdani,Dhiraj Hans,Shantanu Mehta,Ajay Srinivasan,K. Anil,R. L. Madhusudhan,Jaya Patel,Amit Singh,Rajeshwar Rao,Santosh Gangireddy,Rudrappa Patil,Swarnendu Kaviraj,Sanjay Singh,Darrick Carter,Steve Reed,David C. Kaslow,Ashley Birkett,Virander S. Chauhan,Chetan E. Chitnis
DOI: https://doi.org/10.1038/s41541-018-0083-3
2018-09-28
npj Vaccines
Abstract:Reticulocyte invasion by Plasmodium vivax requires interaction of the Duffy-binding protein (PvDBP) with host Duffy antigen receptor for chemokines (DARCs). The binding domain of PvDBP maps to a cysteine-rich region referred to as region II (PvDBPII). Blocking this interaction offers a potential path to prevent P. vivax blood-stage growth and P. vivax malaria. This forms the rationale for development of a vaccine based on PvDBPII. Here we report results of a Phase I randomized trial to evaluate the safety and immunogenicity of recombinant PvDBPII formulated with glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE). Thirty-six malaria-naive, healthy Indian male subjects aged 18–45 years were assigned into three cohorts corresponding to doses of 10, 25 and 50 µg of PvDBPII formulated with 5 µg of GLA-SE. Each cohort included nine PvDBPII/GLA-SE vaccinees and three hepatitis B control vaccine recipients. Each subject received the assigned vaccine intramuscularly on days 0, 28 and 56, and was followed up till day 180. No serious AE was reported and PvDBPII/GLA-SE was well-tolerated and safe. Analysis by ELISA showed that all three doses of PvDBPII elicited antigen-specific binding-inhibitory antibodies. The 50 µg dose elicited antibodies against PvDBPII that had the highest binding-inhibitory titres and were most persistent. Importantly, the antibody responses were strain transcending and blocked receptor binding of diverse PvDBP alleles. These results support further clinical development of PvDBPII/GLA-SE to evaluate efficacy against sporozoite or blood-stage challenge in controlled human malaria infection (CHMI) models and against natural P. vivax challenge in malaria endemic areas.
immunology,medicine, research & experimental